Cancer Network spoke with Suresh S. Ramalingam, MD, of Emory University, about pemetrexed, bevacizumab, or both for advanced non-squamous NSCLC.
Cancer Network spoke with Taofeek Kunle Owonikoko, MD, PhD, of Emory University, about talazoparib for patients with HRRD-positive stage IV squamous cell lung cancer.
Cancer Network spoke with Kathryn Cecilia Arbour, MD, of Memorial Sloan-Kettering Cancer Center, about the most recent research on checkpoint inhibitors in oncology.
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.
Cancer Network spoke with Patricia Eifel, MD, of the University of Texas MD Anderson Cancer Center, about the current shifts in the treatment of cervical cancer.
Cancer Network spoke with Hala Borno, MD, of the University of California, San Francisco, about addressing the disparities in access to clinical trials and treatments for patients with prostate cancer.
Cancer Network spoke with Chiara Cremolini, MD, about the updated results of the phase III randomized strategy study TRIBE2, which looked at the first- and second-line treatment of unresectable metastatic colorectal cancer.
Cancer Network spoke with Daniel McFarland, DO, of Memorial Sloan Kettering Cancer Center, about building programs to prevent burnout and suicide in oncology providers.
Cancer Network spoke with Debu Tripathy, MD, Chair of Breast Medical Oncology at MD Anderson Cancer Center, on how ribociclib plus hormone therapy extends survival for patients with premenopausal advanced HR-positive breast cancer.
In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, discusses combo docetaxel/trametinib in G12C or non-G12C KRAS mutation-positive, recurrent NSCLC.